ÂÜÀòÂÒÂ×

Nageatte Ibrahim, M.D. is an experienced oncology specialist currently serving as the Oncology Chief Medical Officer at Innovent Biologics since April 2024. Previously, Nageatte held several prominent positions at Merck from September 2014 to March 2024, including Vice President of Oncology, where responsibilities encompassed global clinical development. Nageatte's expertise in melanoma was further demonstrated at Penn Medicine as an Assistant Professor of Medicine, as well as in roles at GSK, Dana-Farber Cancer Institute, Brigham and Women's Hospital, and Harvard Medical School. Nageatte's education includes a Doctor of Medicine degree from Tufts Medical Center and undergraduate studies in Molecular Biology and Biochemistry from Rutgers University.